OTV

What OTV does

OTV is a digital health venture capital fund, formerly Olive Tree Ventures, with offices in Tel Aviv, Israel and New York, USA. Founded by partners who have been working together since 2014 and who collectively founded seven prior companies generating over $4 billion in exit value, OTV invests in mid-growth stage digital health startups at Series A or later. The firm closed its first dedicated fund of $170 million in March 2021 and manages a portfolio of approximately 12 companies spanning telehealth (TytoCare, Lemonaid Health), AI-driven genomics interpretation (Emedgene), digital microscopy and AI-enabled cell morphology (Scopio Labs), objective pain monitoring (Medasense NOL), contact-free cardiopulmonary monitoring (Donisi Health), GI services (Hygieacare), driver/in-cabin monitoring (CU-BX), surgical fixation devices (Via Surgical), AR/VR collaboration (Campfire), and smart glass materials (Gauzy).

The fund's core value proposition is hands-on operating expertise combined with a curated network of multinational corporations, leading hospitals across the US/Europe/Asia, and global medical device companies that portfolio companies can leverage for clinical validation, regulatory clearance, and market access. Multiple portfolio companies have secured tier-one strategic partnerships — Siemens Healthineers for global distribution of Scopio's X100/X100HT, Beckman Coulter for hematology workcell integration, LG Electronics for T-OLED displays, and Illumina's Center of Excellence in Israel — and have achieved FDA De Novo clearances (Scopio FF-BMA, Medasense NOL/PMD-200) plus ANVISA approval in Brazil. Portfolio exits have been material: Lemonaid Health was acquired by 23andMe (announced July 2023), Emedgene was acquired by Illumina, and Gauzy filed a Form F-1 for an IPO in May 2024.

OTV's revenue model is standard for a venture fund: management fees on committed capital (and later on net invested capital) plus carried interest, typically 20%, on profits from successful portfolio exits. The firm markets to limited partners through a transparency-first approach — quarterly reports, regular updates, and an annual investor summit in Israel — and sources new investments primarily through founder referrals, existing portfolio CEO recommendations, and partnerships with accelerators, universities, and incubators where partners serve as mentors.

Name

OTV

Legal name

Olive Tree Ventures

Website

https://otv.vc

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

OTV is a Tel Aviv- and New York-based digital health venture capital fund investing in mid-growth stage startups at Series A or later, backed by partners who previously founded seven companies generating over $4 billion in exits.

Ownership category

akta.pro rank

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Fund Management Fees and Carried Interest: As a venture capital fund, OTV generates returns through management fees on committed capital and carried interest (typically 20%) on profits from successful portfolio company exits.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

OTV is a digital health venture capital fund that invests capital in mid-growth stage digital health startups (Series A or later) and pairs that capital with strategic guidance, operational support, and introductions to multinational corporations, leading hospitals, and global medical device companies. The firm closed its first dedicated fund of $170 million in March 2021 and manages roughly 12 portfolio companies spanning telehealth, AI diagnostics, genomics, digital microscopy, surgical devices, and AI-driven patient monitoring.

Product overview

OTV is a venture capital firm (formerly Olive Tree Ventures) that invests in mid-growth stage digital health startups. The firm does not itself produce products but manages a portfolio of 12+ digital health portfolio companies. The portfolio includes TytoCare (handheld telehealth exam kit), Lemonaid Health (telehealth platform, now part of 23andMe), CU-BX (driver health monitoring), Donisi Health (contact-free cardiopulmonary monitoring), Emedgene (AI genomics interpretation, now part of Illumina), HyGIeaCare (GI/colonoscopy prep services), Medasense NOL (AI-powered pain monitoring), Scopio Labs (digital microscopy), Via Surgical (soft tissue fixation devices), and Campfire (AR/VR collaboration). OTV provides funding, strategic guidance, and industry connections to these digital health ventures.

Differentiator

Problem solved

Functional benefit

Products and services

• OTV Digital Health Venture Fund
• Portfolio Company Advisory and Operational Support
• LP Investor Reporting and Summit Program

Quantifiable outcome

• Over $4 billion in shareholder value generated by founding 7 successful companies before becoming VC
• +2 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• LG ElectronicsflagshipStrategic or Co-development Partner · 20 May 2024Gauzy and LG Electronics ID Division executed a memorandum of understanding to extend collaboration in advancing Transparent Organic Light Emitting Diode (T-OLED) displays using Gauzy's patented Suspended Particle Device technology.
• Beckman CoultercoreChannel Partner/ Reseller/ Distributor · 6 November 2023Beckman Coulter, a global leader in clinical diagnostics, partnered with Scopio Labs worldwide to accelerate adoption of digital cell morphology platform. Beckman Coulter connects Scopio Labs' digital morphology with hematology workcell for end-to-end digitization.
• Siemens HealthineerscoreChannel Partner/ Reseller/ Distributor · 28 May 2023Siemens Healthineers was granted global rights to distribute Scopio X100 and X100HT digital solutions featuring full-field imaging and AI-powered Decision Support System with remote viewing capabilities.
• IlluminacoreStrategic or Co-development PartnerEmedgene (now an Illumina Company) partnership to automate interpretation of rare genetic disease data into Illumina's TruSight software suite. Illumina also established Center of Excellence in Israel focusing on AI-driven interpretation technology.
• Safety TechminorChannel Partner/ Reseller/ DistributorSafety Tech (a Gauzy company) partners with LUMINATOR TECHNOLOGY GROUP to bring mirrorless driver assistance systems to mass transit bus market. Safety Tech's Camera Monitor System is already chosen by over 40 operators and multiple bus/coach/truck OEMs.
• Multinational Corporations and HospitalscoreStrategic or Co-development PartnerOTV partners with multinational corporations, leading hospitals in US/Europe/Asia, global medical device companies, and multinational digital companies for portfolio companies' product definition, clinical validation, and market access.
• Research FrontierscoreTechnology or IntegrationGauzy licensed Research Frontiers' patented SPD-SmartGlass light-control technology. Following $60M Series D financing, Gauzy acquired Research Frontiers licensee Vision Systems, becoming the largest internationally diversified smart glass technologies company.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Andreessen Horowitz (a16z Bio): Large multi-stage venture firm with a dedicated bio/health fund investing across digital health, biotech, and healthcare services. Directly comparable to OTV as a digital health investor with deep networks and operator partners, though significantly larger in AUM and team size.
• General Catalyst: Multi-stage venture firm with a significant healthcare practice spanning digital health, healthcare services, and healthtech infrastructure. Comparable to OTV as a digital health investor with operator-led thesis and global LP base, but at materially larger fund size.
• Bessemer Venture Partners: Long-tenured venture firm with a dedicated healthcare practice investing across digital health, biotech, and healthcare services. Comparable to OTV as a multi-stage digital health investor with global presence, though with a much larger and more diversified fund portfolio.
• Khosla Ventures: Multi-stage venture firm with a substantial healthcare and digital health practice investing from seed through growth. Comparable to OTV as an operator-driven digital health investor, though with significantly broader sector coverage and larger fund vintages.
• New Enterprise Associates (NEA): One of the largest venture firms globally with a deep healthcare practice spanning digital health, medical devices, and biotech. Comparable to OTV as a digital health investor with multi-stage deployment, though with a much larger team and longer track record.
• Founders Fund: Multi-stage venture firm with a meaningful healthcare and biotech portfolio, known for founder-led investing. Comparable to OTV's operator-GP thesis and high-conviction digital health bets, though OTV is more sector-concentrated.

Direct peers

• Define Ventures: Early-to-growth stage venture firm exclusively focused on digital health, led by operator-investors. One of the closest direct peers to OTV in digital health-only thesis, fund size, and stage focus, though based in San Francisco rather than Israel/NY.
• Section 32: Digital health-focused venture firm founded by Bill Maris (ex-Google Ventures) investing in growth-stage healthcare and biotech companies. Closely comparable to OTV as a digital health-focused growth investor with operator-GP branding.
• Oak HC/FT: Specialist venture and growth equity firm exclusively focused on healthcare services and financial technology. Highly comparable to OTV as a thesis-driven, sector-focused investor, though typically deploying larger growth-stage checks.
• Flare Capital Partners: Early-stage venture firm exclusively focused on digital health, investing across Series A and B in health tech, tech-enabled services, and digital therapeutics. Comparable to OTV as a digital health-focused specialist, though earlier-stage focused with a smaller fund size.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/olive-tree-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments17 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OTV